Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 97

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 97
---
:

| • | the success of competitive products or technologies; |

| • | regulatory actions; |

| • | actual or anticipated changes in our growth rate relative to our competitors; |

| • | announcements by us or our competitors of new products, significant acquisitions, strategic partnerships, 
 joint ventures, collaborations or capital commitments;                                                    |

| • | the progress of preclinical development, laboratory testing and clinical trials of our product candidates 
 or those of our competitors;                                                                              |

| • | the results from our clinical programs and any future trials we may conduct; |

| • | developments in the clinical trials of potentially similar competitive products; |

| • | EMA, MHRA, FDA or international regulatory or legal developments; |

| • | failure of any of our product candidates, if approved, to achieve commercial success; |

| 47 |

| • | developments or disputes concerning patent applications, issued patents or other proprietary intellectual 
 property rights;                                                                                          |

| • | the recruitment or departure of key personnel; |

| • | the level of expenses related to any of our product candidates or clinical development programs; |

| • | litigation or public concern about the safety of our products; |

| • | actual or anticipated changes in estimates as to financial results, development timelines or recommendations 
 by securities analysts;                                                                                      |

| • | actual and anticipated fluctuations in our operating results; |

| • | variations in our financial results or those of companies that are perceived to be similar to us; |

| • | share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; |

| • | announcements or expectations of additional financing efforts; |

| • | rumors relating to us or our competitors; |

| • | sales of our Depositary Shares by us, our insiders or our other shareholders; |

| • | changes in the structure of healthcare payment systems; |

| • | market conditions in the pharmaceutical and biotechnology sectors, or general volatility in the market 
 due to other factors;                                                                                  |

| • | third party reimbursement policies; |

| • | Brexit and any resulting economic or currency volatility; |

| • | developments concerning current or future collaborations, strategic alliances, joint ventures or similar 
 relationships; and                                                                                       |

| • | reviews of long-term values of our assets, which could lead to impairment charges that could reduce our 
 earnings.                                                                                               |

These and other market and
industry factors may cause the market price and demand for our Depositary Shares to fluctuate substantially, regardless of our actual
operating performance,